Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:578-584

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aalto-Setälä, K.
Right arrow Articles by Saikku, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aalto-Setälä, K.
Right arrow Articles by Saikku, P.
Related Collections
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Genetically altered mice
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:578.)
© 2001 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Chlamydia pneumoniae Does Not Increase Atherosclerosis in the Aortic Root of Apolipoprotein E–Deficient Mice

Katriina Aalto-Setälä; Kirsi Laitinen; Leena Erkkilä; Maija Leinonen; Matti Jauhiainen; Christian Ehnholm; Minna Tamminen; Mirja Puolakkainen; Ilkka Penttilä; Pekka Saikku

From the Department of Internal Medicine (K.A.-S.), Tampere University Hospital, and the Department of Medical Biochemistry (K.A.-S.), University of Tampere, Tampere; the Department of Public Health Sciences (K.L.), University of Helsinki, Helsinki; the National Public Health Institute (L.E., M.L.), Oulu; the National Public Health Institute (M.J., C.E.), Department of Biochemistry, Helsinki; the Department of Internal Medicine and Biocenter Oulu (M.T.), University of Oulu, Oulu; the Haartman Institute (M.P.), Department of Virology, University of Helsinki, Helsinki; the Department of Clinical Chemistry (I.P.), Kuopio University Hospital, Kuopio; and the Department of Microbiology (P.S.), University of Oulu, Oulu, Finland.

Correspondence to K. Aalto-Setälä, Tampere University Hospital, Department of Internal Medicine, PO Box 607, FIN-33101 Tampere, Finland. E-mail lokaaa{at}uta.fi

Abstract—In epidemiological studies, an association between cardiovascular disease and Chlamydia pneumoniae (C pneumoniae) infection has been observed. Although C pneumoniae has been shown to be present in atherosclerotic lesions, a causal relationship between C pneumoniae infection and atherosclerosis has not been demonstrated. To study this question, we used 2 strains of apolipoprotein (apo) E–deficient mice. Eight-week-old mice on an FVB background that were maintained on either a low- or a high-fat diet were infected 3 times at 1-week intervals with C pneumoniae, and atherosclerotic lesions were measured in the aortic root at 10 weeks after the primary infection. In each of the diet groups, no difference in the extent of atherosclerosis could be observed between the C pneumoniae–infected and control animals. In further studies, 2 strains of apoE-deficient mice (FVB or C57BL/6J background) were infected 4 times at 3- to 4-week intervals, and the extent of atherosclerosis was analyzed 18 weeks later. The mice were kept on either a low- or a high-fat diet. The high-fat diet increased atherosclerosis, and a difference in atherosclerosis susceptibility between the mouse strains was observed. However, C pneumoniae infection did not influence lesion size in either mouse strain. On the other hand, C pneumoniae could not be demonstrated by polymerase chain reaction in any of the atherosclerotic lesions of the infected animals studied. A small decrease in serum cholesterol and triglyceride levels 3 days after the primary infection occurred, but after that no differences in serum lipid levels compared with those in noninfected animals were evident. In the myocardium of C pneumoniae–infected mice, no inflammatory signs could be observed. We conclude that under the experimental conditions used, C pneumoniae infection does not accelerate atherogenic changes in the aortic root of apoE-deficient mice.


Key Words: C pneumoniae infection • atherosclerosis • apoE-deficient mice • animal model




This article has been cited by other articles:


Home page
J. Immunol.Home page
Y. Naiki, R. Sorrentino, M. H. Wong, K. S. Michelsen, K. Shimada, S. Chen, A. Yilmaz, A. Slepenkin, N. W. J. Schroder, T. R. Crother, et al.
TLR/MyD88 and Liver X Receptor {alpha} Signaling Pathways Reciprocally Control Chlamydia pneumoniae-Induced Acceleration of Atherosclerosis
J. Immunol., November 15, 2008; 181(10): 7176 - 7185.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Sugita, H. Sugita, and M. Kaneki
Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1390 - 1395.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A.D. Hauer, P. de Vos, N. Peterse, H. ten Cate, Th.J.C. van Berkel, F.R.M. Stassen, and J. Kuiper
Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/- mice
Cardiovasc Res, January 1, 2006; 69(1): 280 - 288.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Yang, D. Coriolan, K. Schultz, D. T. Golenbock, and D. Beasley
Toll-Like Receptor 2 Mediates Persistent Chemokine Release by Chlamydia pneumoniae-Infected Vascular Smooth Muscle Cells
Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2308 - 2314.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
G Arno, J C Kaski, D A Smith, J P Akiyu, S E Hughes, and C Baboonian
Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques
Heart, April 1, 2005; 91(4): 521 - 525.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. D. de Kruif, E. C.M. van Gorp, T. T. Keller, J. M. Ossewaarde, and H. ten Cate
Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research
Cardiovasc Res, February 1, 2005; 65(2): 317 - 327.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku
Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. S. Burnett, S. Durrani, E. Stabile, M. Saji, C. W. Lee, T. D. Kinnaird, E. P. Hoffman, and S. E. Epstein
Murine Cytomegalovirus Infection Increases Aortic Expression of Proatherosclerotic Genes
Circulation, February 24, 2004; 109(7): 893 - 897.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. V. Kalayoglu, P. Libby, and G. I. Byrne
Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease
JAMA, December 4, 2002; 288(21): 2724 - 2731.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
K. P. Karunakaran, J. F. Blanchard, A. Raudonikiene, C. Shen, A. D. Murdin, and R. C. Brunham
Molecular Detection and Seroepidemiology of the Chlamydia pneumoniae Bacteriophage ({Phi}Cpn1)
J. Clin. Microbiol., November 1, 2002; 40(11): 4010 - 4014.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Bea, E. Blessing, B. Bennett, M. Levitz, E. P. Wallace, and M. E. Rosenfeld
Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering
Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1832 - 1837.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R Ezzahiri, H.J.M.G Nelissen-Vrancken, H.A.J.M Kurvers, F.R.M Stassen, I Vliegen, G.E.L.M Grauls, M.M.L van Pul, P.J.E.H.M Kitslaar, and C.A Bruggeman
Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice
Cardiovasc Res, November 1, 2002; 56(2): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
E. Blessing, L. A. Campbell, M. E. Rosenfeld, and C.-c. Kuo
Chlamydia pneumoniae and Hyperlipidemia Are Co-Risk Factors for Atherosclerosis: Infection Prior to Induction of Hyperlipidemia Does Not Accelerate Development of Atherosclerotic Lesions in C57BL/6J Mice
Infect. Immun., September 1, 2002; 70(9): 5332 - 5334.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. C. Kuo, L. A. Campbell, M. E. Rosenfeld, G. Caligiuri, M. Rottenberg, H. Wigzell, G. K. Hansson, and A. Nicoletti
Chlamydia pneumoniae Infection and Atherosclerosis: Methodological Considerations Response
Circulation, January 29, 2002; 105 (4): e34 - e34.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. K. Hansson
Immune Mechanisms in Atherosclerosis
Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1876 - 1890.
[Abstract] [Full Text] [PDF]